Esophageal Motility Disorders — Achalasia and Others
Contents (8)
Esophageal motility disorders represent a heterogeneous group of conditions characterized by abnormal esophageal muscle contraction and/or impaired relaxation of the lower esophageal sphincter (LES), resulting in dysphagia and esophageal dysfunction. Achalasia is the most clinically significant primary motility disorder, affecting approximately 1 per 100,000 population annually with peak incidence in the 5th-6th decade of life. These disorders carry important diagnostic and therapeutic implications because they require specific interventions beyond simple antireflux management and can lead to severe complications including aspiration pneumonia, malnutrition, and esophageal dilation. Understanding the mechanistic differences between achalasia, diffuse esophageal spasm (DES), ineffective esophageal motility (IEM), and secondary motility disorders is essential for appropriate diagnosis and management. Board examinations frequently test the distinction between these conditions and recognition of red flags requiring intervention.
The pathophysiologic basis of esophageal motility disorders involves disruption of the coordinated neuromuscular mechanisms that normally propel food distally and regulate sphincter function. The esophageal motor system requires intact innervation via the vagus nerve (CN X), functional enteric neurons within the myenteric plexus, and coordinated smooth muscle contraction.
Key Mechanism 1: Loss of Inhibitory Innervation in Achalasia
Achalasia results from selective degeneration of inhibitory neurons within the myenteric plexus, particularly those releasing nitric oxide (NO) and vasoactive intestinal peptide (VIP). These inhibitory neurotransmitters normally mediate the "receptive relaxation" of the LES in response to esophageal distension and swallowing. The mechanism involves:
- Progressive neuronal loss, with 50-90% depletion of ganglion cells in the LES region
- Loss of neuronal nitric oxide synthase (nNOS)-expressing neurons, which impairs NO signaling
- Reduced VIP-containing neurons, diminishing the relaxation response
- This inhibitory deficit leads to unopposed cholinergic (excitatory) input via acetylcholine, resulting in a hypertensive, non-relaxing LES that fails to open appropriately during swallowing
- The pathologic process may be autoimmune (anti-HU antibodies detected in some patients), infectious (possibly prior Chagas disease from Trypanosoma cruzi), or idiopathic degenerative
Key Mechanism 2: Impaired Esophageal Body Peristalsis
Beyond LES dysfunction, achalasia involves progressive loss of normal primary and secondary peristaltic waves in the esophageal body due to:
- Degeneration of myenteric neurons throughout the esophagus, not isolated to the LES
- Loss of coordinated sequential contraction patterns
- Replacement of neural elements with fibrosis
- Resultant aperistalsis or severely ineffective contractions that cannot propel a bolus
- Progressive esophageal dilation occurs as intraluminal pressures increase and muscle wall compliance changes, creating a functional megaesophagus
Key Mechanism 3: Smooth Muscle Changes and Secondary Achalasia Development
Over time, chronic outflow obstruction induces structural esophageal changes:
- Smooth muscle hypertrophy and fibrosis, increasing wall thickness and reducing elasticity
- Loss of ganglion cells extends proximally in chronic disease
- Secondary achalasia may develop from malignancy (especially gastric cardia adenocarcinoma, lymphoma) or chronic reflux disease, which can trigger neuronal loss through inflammatory mechanisms
- These secondary forms share the functional phenotype (high LES pressure, absent relaxation) but differ in etiology
Additional Mechanisms in Other Motility Disorders
- Diffuse Esophageal Spasm (DES): Abnormal, repetitive contractions occurring spontaneously or after swallowing; mechanism involves dysregulation of excitatory signaling and possibly increased sensitivity to acetylcholine; some evidence for altered serotonin signaling
- Ineffective Esophageal Motility (IEM): Reduced amplitude of contractions (<30 mmHg) or high proportion of failed contractions; heterogeneous etiology including mild myogenic dysfunction, neural dysfunction, or chronic reflux disease causing persistent inflammation
- Scleroderma-Related Motility Disorder: Collagen deposition and smooth muscle fibrosis lead to patulous LES (dilated, incompetent) with aperistalsis, causing severe reflux rather than obstruction
Primary (Idiopathic) Achalasia
The majority of achalasia cases (~90%) are primary idiopathic disease with unknown etiology. Genetic predisposition is suggested by rare familial clustering and association with certain HLA haplotypes, though no single gene mutation explains most cases. Emerging evidence supports a multifactorial model involving genetic susceptibility, autoimmune mechanisms (circulating anti-HU, anti-Hu antibodies in ~5% of achalasia patients), and possibly viral triggers, though causative agents remain unproven.
Secondary Achalasia — Malignancy
Malignant obstruction at the gastroesophageal junction (GEJ) can mimic achalasia clinically and manometrically, representing "pseudoachalasia." Risk increases significantly after age 60 and with recent symptom onset (<6 months). Gastric cardia adenocarcinoma is most common, followed by gastric lymphoma and metastatic disease to the GEJ. Endoscopic ultrasound (EUS) and careful inspection of the GEJ are critical to exclude malignancy before definitively diagnosing idiopathic achalasia.
Secondary Achalasia — Chagas Disease
In Central and South America, chronic Chagas disease caused by Trypanosoma cruzi is a major cause of secondary achalasia through parasite-induced destruction of myenteric neurons, creating an "American achalasia." Serology for anti-*T. cruzi* antibodies should be obtained in endemic regions.
Secondary Achalasia — Other Causes
- Post-fundoplication achalasia syndrome (iatrogenic, following anti-reflux surgery)
- Amyloidosis
- Sarcoidosis
- Parkinson's disease and other neurodegenerative conditions
- Chronic reflux disease with prolonged acid exposure
Diffuse Esophageal Spasm Risk Factors
Less clearly defined than achalasia; possible associations include anxiety, depression, and chronic stress. Some cases follow esophageal injury (caustic ingestion, radiation). Idiopathic DES is often diagnosed in patients with significant psychiatric comorbidity, though causality is unclear.
Ineffective Esophageal Motility Risk Factors
Chronic gastroesophageal reflux disease (GERD) is strongly associated and may be causal, with acid-induced inflammation and neural dysfunction. IEM can also result from diabetic neuropathy, connective tissue diseases, or anticholinergic medications.
Cardinal Symptom 1: Progressive Dysphagia to Solids and Liquids
The classic presentation of achalasia is dysphagia that is paradoxically worse for liquids than solids — a key distinguishing feature from mechanical obstruction. The patient experiences a sensation of food or liquid sticking in the mid-chest immediately after swallowing, with the obstruction occurring at the gastroesophageal junction. Over months to years, symptom progression is characteristic; early disease may involve solids preferentially, but as the esophagus dilates and loses peristalsis, liquids become equally or more problematic. The mechanism is that gravity cannot assist fluid passage through the non-relaxing LES, whereas solids may slowly dribble through via gravity and pressure buildup proximal to the obstruction.
Cardinal Symptom 2: Regurgitation of Undigested Food
Patients report regurgitation of food consumed hours or even a day earlier, without preceding nausea or vomiting. This occurs because food accumulates in the dilated esophageal body and eventually overflows retrograde, particularly at night or when supine, leading to aspiration risk. Notably, regurgitation in achalasia is non-acidic (in contrast to reflux disease), as stomach contents have not yet reached the esophagus.
Cardinal Symptom 3: Chest Pain
Mid-chest or substernal pain occurs in 60% of achalasia patients, often described as pressure or discomfort, and can be severe enough to raise concern for cardiac ischemia. Pain results from esophageal distension and spasm-like contractions against the obstructed LES. This symptom can wax and wane, creating diagnostic confusion; serial electrocardiograms may be necessary to exclude coronary artery disease in older patients presenting with chest pain attributed to achalasia.
Additional Symptom: Heartburn and Reflux Sensation
Paradoxically, patients may report heartburn-like discomfort, which is actually caused by esophageal distension and acidification from bacterial overgrowth in the stagnant esophageal contents, not from reflux of gastric acid into the esophagus. The LES is non-relaxing and thus theoretically protective against reflux, but occasionally reflux can occur if LES pressure is very low in late-stage disease.
Physical Exam Findings
- Weight loss: Progressive weight loss is common, often 5-10 kg over months to years, reflecting decreased caloric intake due to dysphagia
- Signs of malnutrition: May see muscle wasting, loss of skin turgor, pale conjunctivae (if concurrent anemia), though physical exam is often unremarkable
- Halitosis: Foul-smelling breath may be noted due to bacterial fermentation of retained food
- Absence of focal neurologic signs: Unlike myasthenia gravis or other neuromuscular diseases, cranial nerves and strength are normal
Clinical Variants and Presentations
- Diffuse Esophageal Spasm (DES): Presents with intermittent, often severe substernal chest pain (can mimic angina), dysphagia to solids predominantly, and symptoms provoked by hot or cold liquids. Dysphagia is variable and often mild. Contractions are not aperistaltic but rather disorganized and repetitive.
- Ineffective Esophageal Motility (IEM): Often asymptomatic and discovered incidentally, or presents with mild dysphagia and prominent reflux symptoms. Symptoms are often attributed to GERD.
- Chagas Disease-Related Achalasia: Indistinguishable clinically from idiopathic achalasia; travel history to endemic areas or immigrant status is the key diagnostic clue.
Clinical History and Red Flags for Secondary Achalasia
A detailed history should assess symptom onset (acute vs. insidious), duration, and progression. "Red flags" favoring secondary achalasia or malignancy include:
- Age >60 at symptom onset
- Symptom duration <6 months (more common in pseudoachalasia)
- Significant weight loss (>10-15% body weight)
- Odynophagia (painful swallowing)
- Absence of air-fluid level on chest X-ray (lower sensitivity for dilated esophagus)
Endoscopy (EGD) — First Diagnostic Step
Endoscopy is essential in the diagnostic workup to exclude mechanical obstruction and malignancy. In achalasia, findings include:
- Closed or mildly patulous GEJ with resistance to passage of the scope
- Retained food debris and saliva in the esophageal lumen despite fasting
- Dilated esophagus with atrophic mucosa, sometimes with a thin, smooth narrowing at the GEJ ("bird beak" appearance on barium swallow, not endoscopy)
- Normal mucosa without ulceration, erythema, or Barrett's changes (absence of Barrett's helps distinguish achalasia from chronic reflux)
- Absence of malignancy — if visualization of GEJ is difficult due to retained material, EUS may be warranted
Barium Esophagography
While less sensitive than manometry, barium swallow is highly specific for achalasia and provides anatomic detail:
- Classic "bird beak" appearance: A smooth, tapered narrowing at the GEJ with an abrupt transition to a dilated esophagus above
- Air-fluid level: May be present if significant retention
- Smooth esophageal walls without ulceration or irregular narrowing (distinguishes from carcinoma)
- Loss of normal esophageal peristalsis — viewed on fluoroscopy as stasis rather than organized proximal-to-distal contraction
- Sensitivity ~95% for achalasia when classic findings present; less sensitive in early disease when esophageal dilation is minimal
Esophageal Manometry — Gold Standard for Diagnosis
High-resolution esophageal manometry (HREM) is the gold standard for confirming primary achalasia. The Chicago Classification (updated 2021) provides standardized diagnostic criteria:
Achalasia Diagnostic Criteria (Chicago Classification v3.0)
- Elevated integrated relaxation pressure (IRP) of the LES >26 mmHg (median value, measured over 4-second window during relaxation after swallowing)
- Absent normal esophageal peristalsis (defined as <20% of swallows with ≥75% of the swallow duration showing contractions with pressure >20 mmHg)
Achalasia is further subtyped based on post-relaxation contraction patterns:
- Type I (Classic/Obstructive): Minimal esophageal pressurization; worst prognosis
- Type II (With Compression): Panesophageal pressurization (20-30 seconds); better response to treatment
- Type III (Spastic): Premature (rapid) contractions; associated with DES-like features; worse treatment response
Sensitivity and Specificity: Manometry has 95%+ specificity for achalasia when diagnostic criteria are met. IRP >26 mmHg is the most discriminatory parameter.
High-Resolution Esophageal Imaging (HRiM)
Combines manometry with intraluminal imaging to visualize esophageal anatomy during manometry, improving detection of secondary causes (malignancy, fibrosis, external compression).
Endoscopic Ultrasound (EUS)
Indicated when there is clinical suspicion for secondary achalasia (short symptom duration, weight loss, age >60):
- Can visualize GEJ musculature and detect infiltrative processes, lymphadenopathy, or tumors
- Increased GEJ wall thickness (>5 mm) may suggest malignancy
- Sensitivity and specificity of 90-95% for detecting GEJ carcinoma
Laboratory Tests
- Anti-HU antibody serology: May be positive in ~5% of achalasia patients; suggests autoimmune pathogenesis but not routinely tested
- **Anti-*Trypanosoma cruzi* serology**: Indicated in patients from endemic regions (Central/South America)
- CBC and metabolic panel: To assess nutritional status, anemia (from malabsorption), and electrolytes
Differential Diagnosis Considerations
- Pseudoachalasia (secondary achalasia from malignancy): Consider if age >60, rapid symptom progression, short duration, significant weight loss, or abnormal imaging findings; EUS helpful
- Diffuse Esophageal Spasm: Manometry shows preserved or incomplete LES relaxation with repetitive, non-peristaltic contractions (>20% of swallows); chest pain often predominant
- Ineffective Esophageal Motility: Low-amplitude contractions (<30 mmHg in >50% of swallows); LES pressures and relaxation are normal; mild or no dysphagia
- GERD with reflux-induced dysphagia: Positive reflux symptoms, evidence of reflux on pH monitoring, Barrett's esophagus on biopsy; normal LES relaxation on manometry
- Mechanical obstruction (peptic stricture, webs, rings): Abrupt narrowing on barium swallow, irregular or friable appearance on endoscopy, history of reflux or caustic ingestion
First-Line Treatment: Pneumatic Dilation
Pneumatic dilation (PD) of the LES is the most effective non-surgical definitive treatment for achalasia, with short-term (6-month) symptom relief in 70-90% of patients. The procedure is performed under endoscopic guidance and involves placement of a specially designed rigid balloon across the LES and inflation to disrupt the circular muscle fibers by mechanical force, creating a controlled "tear" in the sphincter. The mechanism of symptom relief is **permanent
Complications of untreated disease
- Aspiration pneumonia / nocturnal aspiration: retained esophageal contents overflow retrograde when supine; signals include recurrent nocturnal cough, foul sputum, and a new lower-lobe infiltrate. Acute hypoxemic respiratory failure or a large-volume aspiration event is an emergency requiring airway protection, NPO status, and treatment per IDSA/ATS community-acquired pneumonia guidance.
- Malnutrition and weight loss: chronic reduced caloric intake; falling weight, sarcopenia, and micronutrient deficiency. Progressive weight loss in an older patient with short symptom duration should instead prompt re-evaluation for pseudoachalasia.
- Megaesophagus / "sigmoid" esophagus: end-stage decompensation of the dilated, aperistaltic body; barium shows a tortuous, angulated esophagus that no longer empties. This predicts failure of dilation or myotomy and is the main indication for esophagectomy.
- Food impaction and stasis esophagitis: bacterial fermentation and Candida overgrowth in retained food; halitosis, odynophagia, white plaques on endoscopy. Complete obstruction with inability to handle secretions is an emergency requiring urgent endoscopic disimpaction.
- Squamous cell carcinoma: chronic stasis-induced mucosal inflammation raises relative risk substantially, though absolute risk remains low and latency is typically over a decade. The ACG achalasia guideline does not endorse routine endoscopic cancer surveillance; new or changing dysphagia after successful therapy is the finding that warrants repeat endoscopy.
- Massive esophageal dilation with airway or mediastinal compression: rare; stridor or acute dyspnea is an emergency.
Complications of treatment
- Esophageal perforation after pneumatic dilation: the intended controlled muscle tear extends full thickness. Suspect with severe post-procedure chest pain, fever, tachycardia, subcutaneous emphysema, or a Hamman crunch; confirm with water-soluble contrast esophagram or CT. This is a surgical emergency — NPO, broad-spectrum antibiotics, surgical consultation.
- Post-myotomy GERD: ablating the LES removes the antireflux barrier. Highest after POEM, which is why the ACG and SAGES recommend pairing laparoscopic Heller myotomy with a partial (Dor or Toupet) fundoplication and monitoring POEM patients for reflux, peptic stricture, and Barrett's esophagus; long-term PPI is often required.
- Botulinum toxin injection: effect wanes within months and repeated injections cause submucosal fibrosis that complicates later myotomy.
- Pharmacologic therapy (nitrates, calcium channel blockers): headache, hypotension, pedal edema; marginal efficacy.
- **Dysphagia to solids and liquids from the outset** is the single most tested discriminator: motility disorder, not mechanical obstruction. Solids-only dysphagia that later includes liquids suggests stricture, ring, or carcinoma.
- Best next step in any new dysphagia is upper endoscopy, not manometry. Endoscopy excludes malignancy and mechanical lesions; only after a normal EGD does high-resolution manometry confirm achalasia (elevated IRP plus absent peristalsis). Barium bird's beak is suggestive, not confirmatory.
- Pseudoachalasia is the classic trap: age over 60, symptoms under 6 months, and out-of-proportion weight loss point to gastric cardia adenocarcinoma or another infiltrating tumor. The answer is targeted evaluation of the GEJ (biopsy, EUS/CT), not dilation.
- Chagas disease is the association examiners reuse: an immigrant from Central or South America with achalasia should also raise suspicion for megacolon and Trypanosoma cruzi cardiomyopathy (biventricular dilation, apical aneurysm, right bundle branch block with left anterior fascicular block).
- Distal esophageal spasm: intermittent chest pain mimicking angina, corkscrew or rosary bead esophagus on barium, premature contractions with normal LES relaxation on manometry. Rule out cardiac ischemia first. Hypercontractile (jackhammer) esophagus shows a markedly elevated distal contractile integral.
- Scleroderma is achalasia's mirror image: fibrosis of the distal smooth muscle produces aperistalsis with a patulous, hypotensive LES, so the problem is severe reflux and peptic stricture, not obstruction. Treat with a PPI (per ACG GERD guidance); myotomy and dilation are wrong answers.
- Therapy is definitive, not medical: per the ACG achalasia guideline, pneumatic dilation, laparoscopic Heller myotomy with partial fundoplication, and POEM are comparably effective in appropriate candidates; nitrates and calcium channel blockers are weakly effective, and botulinum toxin is reserved for poor operative candidates. Type III (spastic) achalasia is the subtype where POEM, with its longer myotomy, is favored.
- Common distractor: treating regurgitation of undigested, non-acidic food as GERD with escalating PPI therapy. Absence of acid taste and regurgitation of food eaten hours earlier point away from reflux.